Clinical and proteomic characterization of acute myeloid leukemia with mutatedRAS-Reference-Cited by-同舟云学术

Clinical and proteomic characterization of acute myeloid leukemia with mutatedRAS

Published:2012-05-08 Issue:22 Volume:118 Page:5550-5559
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kadia Tapan M.,Kantarjian Hagop,Kornblau Steven,Borthakur Gautam,Faderl Stefan,Freireich Emil J.,Luthra Raja,Garcia-Manero Guillermo,Pierce Sherry,Cortes Jorge,Ravandi Farhad

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.27596/fullpdf

Reference34 articles.

1. ras oncogenes in human cancer: a review;Bos;Cancer Res.,1989

2. Targeting RAS signalling pathways in cancer therapy;Downward;Nat Rev Cancer.,2003

3. RAS and leukemia: from basic mechanisms to gene-directed therapy;Beaupre;J Clin Oncol.,1999

4. Implications of NRAS mutations in AML: a study of 2502 patients;Bacher;Blood.,2006

5. Mutations in N-ras predominate in acute myeloid leukemia;Bos;Blood.,1987

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: Venetoclax plus Azacitidine in treatment of acute undifferentiated leukemia;Hematology;2023-12-14

2. Molecular findings in myeloid neoplasms;International Journal of Laboratory Hematology;2023-06-21

3. Obstruction of the biliary tract as a rare presentation of acute myeloid leukemia: A case report;Oncology Letters;2023-05-26

4. TMT-based comprehensive proteomic profiling identifies serum prognostic signatures of acute myeloid leukemia;Open Medicine;2023-01-01

5. Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes;American Journal of Hematology;2022-10-19